NBIX:NASDAQ
Neurocrine Biosciences, Inc
$161.62
arrow_upward
+2.10%(+3.33) 1D
$161.01
arrow_downward
-0.38% (-0.61)todayPre-market
Closed: Jun 22, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NBIX...
Open
$161.17
High
$161.79
Low
$159.32
Mkt. cap
16.25B
Avg. vol.
1.24M
Volume
462.00
P/E ratio
24.86
52-wk high
$169.57
52-wk low
$122.14
EPS
$6.50
Beta
0.40
Shares outstanding
100.55M
No. of employees
2K
Open
$161.17
High
$161.79
Low
$159.32
Mkt. cap
16.25B
Avg. vol.
1.24M
Volume
462.00
P/E ratio
24.86
52-wk high
$169.57
52-wk low
$122.14
EPS
$6.50
Beta
0.40
Shares outstanding
100.55M
No. of employees
2K
Profile
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia.
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids. Wikipedia
About Neurocrine Biosciences, Inc
CEOKevin C. Gorman
Employees2K
Founded1992
HeadquartersSan Diego, California, United States
SectorBiotechnology
Websiteneurocrine.com
AI content may include mistakes. Learn more